Ecological impacts of fluridone and copper sulphate in catfish aquaculture ponds.

Fluridone and copper sulphate are often used for controlling macrophytes and algae in aquaculture ponds. The present study examined the ecological effects of these chemicals on macrophyte, phytoplankton, and zooplankton biomass; plankton community structure; water quality parameters; and fish survival and yield in catfish culture ponds using a randomized complete block design. The estimated half-life of fluridone in the individual ponds ranged from 1.6 d to 10.8 d. Free copper ion activity in ponds treated with copper sulphate was dynamic, ranging from pCu of 7.7 to 8.9 after each application and decreasing to approximately 12 (1 × 10(-12) M) within 1 wk after each application, approaching observed values in control ponds (pCu = 12.3-13.4). No difference in macrophyte biomass was observed among treatments. Fluridone and copper treatments elicited different responses within the phytoplankton community. Copper treatments reduced Cyanophyta biomass but increased biomass of more tolerant taxa among the Chlorophyta and Chrysophyta. Fluridone treatments reduced total phytoplankton biomass including Cyanophyta and increased the sensitivity of Chlorophyta and Chrysophyta to copper. Copper also affected zooplankton community composition as a result of direct toxic effects on sensitive zooplankton taxa (e.g., Cladocera), whereas Copepoda biomass in copper-treated ponds exceeded that in controls. Catfish survival and yield were not significantly different among treatments. The results of the present study suggest that fluridone and copper interact at realistic application rates, increasing the ability to control algae compared with treatments where they are applied alone.

Development of realistic environmental release factors based on measured data: approach and lessons from the EU metal industry.

The assessment of environmental exposure and risks associated with the production or use of a substance on an industrial site includes the estimation of the releases to the environment. In the absence of measured release data on the specific substance, a risk assessor would rely on default release factors to the environmental compartments as developed in international, national, or regional context. Because a wide variety of substances, processes, and uses has to be covered, default release factors are as a rule conservative, usually leading to significant overprediction of releases and hence to overpredicted environmental exposure concentrations and risks. In practice, unrealistic and worst-case predictions do not support a more efficient management of releases and risk. The objective of this article is to propose a more realistic approach to characterize the environmental releases from manufacture, processing, and downstream uses of the metals and their compounds. Although developed in the European Union (EU), this approach can also be used in other regions and in other chemical management systems addressing metals. A database consisting of more than 1300 recent (1993-2010), site-specific measured release factors to air and water of 18 different metals from various EU Member States was compiled and used to calculate average and reasonable worst-case release factors for multiple metal manufacture and industrial use processes. The parameters influencing releases to water were found to depend predominantly on life cycle step (manufacture and/or use), the sector and/or the solid-water partition coefficient (K(d)). The release factors can be used as advanced tier instrument in environmental safety assessments, increasing the realism of the estimates while still keeping a sufficient level of conservatism.

Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells.

Mutation of p53 is rare in Ewing's sarcoma (ES), suggesting that targeting and activation of wild-type p53 may be an effective therapeutic strategy for ES. The recently developed small-molecule MDM2 inhibitor nutlin-3 restores wild-type p53 function, resulting in the inhibition of cancer cell growth and the induction of apoptosis. In the present study, we explored the responsiveness of ES cell lines with wild-type or mutated p53 to nutlin-3. We found that treatment with nutlin-3 increased p53 level and induced p53 target gene expression (MDM2, p21, PUMA) in ES cells with wild-type p53, but not in ES cells with mutated p53. Consistently, nutlin-3 elicited apoptosis only in wild-type p53 cells, as assessed by caspase-3 activity assay and flow cytometric analyses of mitochondrial depolarisation and DNA fragmentation. In addition, we found nutlin-3 to evoke cellular senescence, indicating that nutlin-3 induces pleiotropic anticancer effects in ES. Furthermore, combined treatment with nutlin-3 and an inhibitor of NF-κB produced synergistic antineoplastic activity in ES cells. Our findings suggest that the direct activation of p53 by nutlin-3 treatment may be a useful new therapeutic approach for patients with ES.

Targeting PI3K in neuroblastoma.

PURPOSE: This work employs pharmacological targeting of phosphoinositide 3-kinases (PI3K) in selected neuroblastoma (NB) tumors with the inhibitor AS605240, which has been shown to express low toxicity and relative specificity for the PI3K species γ. METHODS: The expression pattern of PI3K isoforms in 7 NB cell lines and 14 tumor patient samples was determined by Western blotting and immunocytochemistry. The effect of AS605240 on the growth of four selected tumor cell lines was assessed. Two cell lines exhibiting (SK-N-LO) or lacking (SK-N-AS) PI3Kγ expression were chosen for further in vitro analysis, which involved propidium iodide (PI)-based cell cycle staining, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL-staining) of apoptotic cells and analysis of PI3K/Akt-related signaling pathways via Western blotting and translocation experiments. The action of AS605240 in vivo was addressed by xenograft experiments in severe combined immunodeficiency (SCID) mice, thereby comparing SK-N-LO and SK-N-AS derived tumors. Apoptosis induced in SK-N-LO tumors was shown by immunohistochemical TUNEL-staining. RESULTS: Significant expression of PI3Kγ in neuroblastoma patient biopsies and tumor cell lines was detected. AS605240 induced apoptosis in NB cell lines proportional to this expression and suppressed growth of PI3Kγ positive, but not negative, tumors in a xenograft mouse model. No adverse effects of the inhibitor treatment were observed. CONCLUSIONS: Our observations hint to an oncogenic function of PI3Kγ in distinct neuroblastoma entities and reveal PI3K targeting by AS605240 as a promising molecular therapy of these tumors.

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies.

Tumour angioneogenesis is associated with the reexpression of oncofetal fibronectin (oncFn) and tenascin-C (oncTn-C) splice variants, which may serve as targets for antibody-based pharmacodelivery. Knowledge of the vascular distribution and organization in different tumours is of importance for the understanding of tumour vessel formation and might be crucial for therapy. Therefore, human SIP format antibodies against Fn ED-A, Fn ED-B and Tn-C A and C splice domains were used for immunofluorescence labelling in renal, lung, oral, colon, breast and urinary bladder carcinoma specimens and in a renal carcinoma xenograft. The spatial relation to stroma, vessels and vascular basement membrane (vBM) was analysed including CD31 and laminin alpha4 chain antibodies. Renal cell carcinomas and atypical carcinoid of the lung revealed vessel-restricted oncFn and/or oncTn-C depositions; all other entities showed a variable stroma positivity including vessels. The individual pattern of oncFn/oncTn-C incorporation in the vBM depended on tumour type, vessel size and intratumoural heterogeneity. There was a stratification of the vessel wall showing luminal oncFn and extraluminal oncTn-C depositions. As shown in the xenograft, perivascular oncTn-C is provided by carcinoma cells. In conclusion, tumours differ in the pattern of Fn or Tn-C isoform positivity in the vessel wall, potentially representing a tumour type specific endothelial cell-tumour cell-stromal cell interaction. Carcinoma cells themselves are involved in vascular Tn-C matrix organization. Up to antigen distribution, Fn and Tn-C domain antibodies may serve as vehicles for antiangiogenetic and antifibrotic agents; oncFn/oncTn-C based targeting should be adapted individually.

Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.

BACKGROUND: Mesothelin is a promising candidate for tumor-specific therapy because of its limited expression in normal tissues and high expression in several cancers. The expression of the protein mesothelin in hematological malignancies has not yet been analyzed. SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin which is undergoing clinical evaluation in patients with mesothelin-expressing tumors. METHODS AND RESULTS: In this study we show that the mesothelin protein is expressed in leukemic cells from children with acute myeloid leukemia (AML). This finding was confirmed by western blot, immunocytochemistry and real time polymerase chain reaction (PCR). Despite the expression of mesothelin, the patient samples were not sensitive to immunotoxin SS1(dsFv)PE38 in MTT assays. CONCLUSIONS: Primary AML cells express mesothelin but SS1(dsFv)PE38 is not active in killing these cells. Other approaches that utilize mesothelin as a target might be more effective and should be tested against AML cells.

Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia.

BACKGROUND: Monitoring of minimal residual disease (MRD) has become a strong diagnostic tool in acute lymphoblastic leukemia. It is used for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need for more suitable MRD markers. EXPERIMENTAL DESIGN: A stepwise approach which combined genome-wide expression profiling, TaqMan low density arrays, and a TaqMan real-time PCR-based screening was used to identify new markers for the monitoring of MRD in AML. Leukemic cells from 52 children with AML and 145 follow-up samples from 25 patients were analyzed. RESULTS: Seven genes were identified which are vastly overexpressed in many patients with AML compared with healthy bone marrow: CCL23, GAGED2, MSLN, SPAG6, and ST18 as well as the previously described markers WT1 and PRAME. The expression of all genes decreased to normal levels in patients who achieved a continuous complete remission. Elevated levels of at least one gene were found prior to relapse in 7 out of 10 patients who relapsed. CONCLUSIONS: This set of genes should allow a sensitive and specific monitoring of MRD in AML. Notably, some of these markers could also serve as therapeutic targets or might be involved in leukemogenesis. MSLN is already used as a target for immunotherapy in clinical trials in other malignancies.

Rhizotoxicity of cadmium and copper in soil extracts.

Dissolved organic matter (DOM) influences metal speciation in soil solutions and, hence, metal toxicity. Root-elongation experiments were conducted to examine the effect of soil solution components, such as Ca, H, and DOM, on metal rhizotoxicity. A biotic ligand model (BLM) was tested for its ability to predict the rhizotoxicity of Cd and Cu in soil extracts. It was hypothesized that the concentration of Cd and Cu bound to functional groups at the root surface estimated using a BLM would be a better predictor of rhizotoxicity than the free-metal ion activity in solution. Both metals became less toxic at higher DOM, Ca, and H concentrations. Solution speciation and the effect on root growth explained most of the variability observed in the DOM experiments, but not in the cation experiments. It was concluded that Ca and H inhibited the rhizotoxicity of both metals tested. Rhizotoxicity data correlated better with estimates of metal-root complexes that have been estimated with a BLM than with free-metal ion activity or with total metal concentrations. The BLM seems to be a promising approach for predicting metal availability in soils and for assessing the associated risk.

The biotic ligand model for plants and metals: technical challenges for field application.

To improve predictions of phytoavailable metal, the mechanistic bases of bioaccumulation and toxicity of metals to plants can be integrated into a biotic ligand model (BLM). There are a number of significant challenges to the application of the BLM to plants in soils, including reliable measurements of free ion concentrations for the metals of interest in rhizospheric soil solution, as well as other free ions, and concentrations of ligands to which the ions could bind; identification of the simplest model that can adequately predict root accumulation, and the potential for more complex models to add accuracy to the predictions; incorporating the dissociation of labile metal complexes (i.e., nonequilibrium processes) into a BLM, which is an equilibrium model; application of factors in a BLM that adequately describe translocation, in order to estimate metal concentration and speciation in plant shoots. The review concluded that the ability to estimate trace metal speciation in samples of soil solution are not likely to be better than within one order of magnitude of actual, thus this would be an additional source of uncertainty to the predictions of toxicity. Further, regulatory use of the BLM would require mechanistic bases; and, until root ligands associated with toxicity are well characterized, incorporating the ameliorative effects of competitive cations cannot be mechanistically based. As well, a functional BLM for soils with lower metal free ion activities will have to include kinetic data for metal-ligand complexes, as their association/disassociation may constitute a greater metal supply to roots than what would be predicted by the free ion concentration in soil solution. To apply the BLM to trophic transfer where metal concentration in plant shoots is the main focus, a probabilistic approach using experimentally determined root-shoot partitioning of metals might permit estimates of shoot accumulation from root data, to within one or two orders of magnitude.

Polyunsaturated but not conjugated linoleic acid supplementation of leukemic U937 cells can act as an amplification factor for photofrin-mediated photodynamic therapy.

Polyunsaturated fatty acids located in leukemia cell membranes are excellent targets for peroxidation. They can significantly enhance the effectiveness of Photofrin-mediated photodynamic therapy (PDT)-induced cell killing. In this study, the peroxidizability of conjugated fatty acid isomers (9c,11t-linoleic acid and 9c,11c-linoleic acid) and polyunsaturated fatty acids (PUFAs; linoleic acid, gamma-linolenic acid and arachidonic acid) with 2,2'-azo-bis(2-amidinpropane)dihydrochloride, soybean lipoxygenase and photomediated peroxidation are compared with each other. Peroxidation was determined using different methods: by means of gas chromatography to estimate the fatty acid (FA) consumption, by photometry for the level of FA peroxides or phospholipid peroxides and by definition of the content of malondialdehyde for thiobarbituric acid reactive substances (TBARS). The results suggest that the generation of oxidation products from individual FAs indicate a different formation rate of oxidation products. Radical FA peroxides were produced most by polyunsaturated arachidonic acid, followed by linoleic acid and gamma-linolenic acid, whereas conjugated FA isomers did not generate peroxides. Accordingly, the levels of lipid peroxides and TBARS were substantially increased after incorporation and oxidation of polyunsaturated FAs into U937 cells and could significantly enhance the effectiveness of Photofrin-PDT-induced cytotoxicity. The results showed that PUFA, but not conjugated FA supplementation of U937 cells, can act as a PDT amplification factor.

Conjugated linoleic acid modulation of cell membrane in leukemia cells.

This study compared the cellular uptake of pure conjugated linoleic acid isomers (CLA(9c,11t) and CLA(9c,11c)) to linoleic acid (LA) and their effects on polyunsaturated fatty acid (PUFA) synthesis, its metabolism into conjugated long chain fatty acids (FAs) by desaturation and chain-elongation as well as cell proliferation and the associated anticarcinogenic effects on various human leukemia cell lines (K562, REH, CCRF-CEM and U937 cells). Furthermore, selective effects of this individual isomers of CLA on desaturation steps involved in the biosynthesis of PUFAs associated with cell growth were investigated. CLA isomers supplemented in the culture medium was readily incorporated and esterified into phospholipids (PLs) in the four cell lines in a concentration- and time-dependent manner. The incorporation of the specific CLA isomers in PLs was similar to LA. All four incubating leukemia cells (40 microM CLA for 48 h) showed very high cellular CLA content in PLs (range: 32-63 g FA/100 g total phospholipid fatty acid) affected by the nature of CLA and the cell type. Supplementation with CLA or LA altered also cell membrane composition by n-6 PUFA synthesis. Accordingly, CLA metabolism interferes with LA metabolism. We were able to show that CLA isomers are converted by the leukemia cells of the same metabolic pathway into conjugated diene fatty acids (CDFAs) as LA into non-conjugated PUFAs. In this view, the gas chromatography-flame ionization detector detection of major CDFAs (CD-18:3, CD-20:2 and CD-20:3) in cell membrane of CLA-treated cultures resulted from successive Delta6-desaturation, elongation and Delta5-desaturation of CLA isomers. However, in comparison to LA, relatively lower amounts of elongation and/or desaturation metabolites were detected for CLA(9c,11t), and only minor amounts or trace CDFAs were observed for CLA(9c,11c). Furthermore, CLA(9c,11t) revealed only very low levels of CD-20:4 FA and no CLA(9c,11c)-conversion could be detected. The metabolization of CLA indicated that CLA(9c,11c)60 microM) had the CLA type dependent antiproliferative effects. Thus, the 9cis,11trans- and the 9cis,11cis-CLA isomers regulate cell growth and survival in different leukemia cell types through their existence alone and/or by their inhibitory effects of desaturase activity.

Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia.

PURPOSE: The family of multidrug resistance-associated proteins (MRPs) belongs to the ATP-binding cassette superfamily of transporters, which have the ability to function as outward pumps for chemotherapeutic drugs. Their structure, function, and substrate specificity have been studied intensively, but little is known about their clinical relevance in malignant diseases. EXPERIMENTAL DESIGN: In this study, the expression of the MRP2, MRP3, MRP4, MRP5, and SMRP genes was measured using TaqMan real-time PCR in 53 children with de novo acute myeloid leukemia. Nine patients were also analyzed in relapse. RESULTS: MRP3 gene expression was higher in patients who did not achieve remission (P = 0.023). Expression of MRP2 (P = 0.09) or MRP3 (P = 0.041) was associated with a lower rate of survival, and patients who expressed high levels of both genes had a particularly poor prognosis (P < 0.01). No significant association was found for overall survival or remission rate and the expression of MRP4, MRP5, and SMRP. CONCLUSIONS: This study provides first data on the clinical relevance of five MRPs in acute myeloid leukemia patients. The results strongly suggest that MRP3 and possibly also MRP2 are involved in drug resistance in this disease. Those two proteins therefore represent interesting markers for risk-adapted therapy and possible targets for the development of specific drugs to overcome multidrug resistance.

Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia.

In this study, 86 children (58 initial ALL and 28 children with relapsed disease) were investigated for lung resistance protein (LRP) and multidrug resistance related protein (MRPI)-mRNA expression by semiquantitative RT-PCR. The majority of investigated cases demonstrated variable LRP and MRP1 mRNA expression, when normalized for beta-microglobulin expression. LRP and MRPI mRNA expression may be coordinately regulated, as expression of both transcripts was found to be significantly correlated (p = 0.0001). No differences of LRP and MRP expression were observed between initial and relapsed stage patients (LRP: p = 0.89 and for MRP: p = 0.09). The prognostic value of both resistance mechanisms was subjected to Kaplan-Meier analysis for event-free survival. For this analysis the patients were divided into groups with high or low LRP or MRPI mRNA expression by utilizing the median value as the cut-off point. Overexpression of both resistance mechanisms had no prognostic significance in our retrospective study (log-rank test for LRP: p = 0.12 and for MRPI: p = 0.95), however, patients who showed high LRP expression exhibited a lower tendency of remaining in continuous first remission.

Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia.

The breast cancer resistance protein (BCRP), also known as mitoxantrone resistance protein (MXR) or placenta ABC protein (ABC-P), is the second member of the ABCG subfamily of ABC transport proteins (gene symbol ABCG2). BCRP has been detected in acute myeloid leukaemia and in breast, colon and gastric cancer but there has been no reports regarding BCRP expression in acute lymphoblastic leukaemia (ALL). We report the first results of BCRP expression in childhood ALL. Sixty-seven children (47 initial stage, 20 relapses) with ALL were analysed for BCRP gene expression by TaqMan real-time polymerase chain reaction. The expression of BCRP in mononuclear cells obtained from the bone marrow (BM) and peripheral blood (PB) of healthy donors was also investigated. There was no relationship between BCRP expression and age, sex, initial blast cell count, prednisolone response or BM response on d 15 and 33. Patients with T-lineage ALL showed a lower expression of BCRP (P = 0.044). Kaplan-Meier analysis of the relapse-free interval showed no prognostic significance of BCRP expression when different levels of BCRP expression were used as cut-off points. No significant difference in expression of BCRP mRNA was measured between initial-stage and relapsed-stage ALL or between normal MNC obtained from BM and ALL patients. The results indicate a low expression of BCRP in childhood ALL. Relationships between BCRP and clinical, molecular or in vivo resistance characteristics of the patients were not observed.